Mark L. Zangardi

Ruxolitinib for secondary hemophagocytic lymphohistiocytosis

Jonathan H. Sin, Mark L. Zangardi · Hematology/Oncology and Stem Cell Therapy · 2017 · 87 citations · Full text

Medicine, Hematology, Pharmacology +17

Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience

Seth A. Wander, Hyo S. Han, Mark L. Zangardi et al. · Journal of the National Comprehensive Cancer Network · 2021 · 85 citations

Medicine, Oncology, Pharmacology +16

Pilot Randomized Trial of a Pharmacy Intervention for Older Adults with Cancer

Ryan David Nipp, Margaret Ruddy, Charn‐Xin Fuh et al. · The Oncologist · 2018 · 44 citations · Full text

Pharmacy, Oncology, Pharmacy Practice +15

A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC).

Seth A. Wander, Mark L. Zangardi, Andrzej Niemierko et al. · Journal of Clinical Oncology · 2019 · 36 citations

Medicine, Oncology, Pharmacology +17